Intellia Therapeutics (NTLA) Change in Acquisitions & Divestments (2019 - 2026)

Intellia Therapeutics (NTLA) has 8 years of Change in Acquisitions & Divestments data on file, last reported at $113.4 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $113.4 million, down 36.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $486.8 million (down 50.19% YoY), and the FY2025 annual result was $551.7 million, down 48.29% from the prior year.
• Change in Acquisitions & Divestments climbed to $113.4 million in Q1 2026 per NTLA's latest filing, from $94.7 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $321.6 million in Q4 2024 and troughed at $93.7 million in Q1 2022.
• A 5-year average of $192.2 million and a median of $199.7 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2023 and 2025: Change in Acquisitions & Divestments surged 181.24% in 2023, then sank 70.55% in 2025.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $210.2 million in 2022, then decreased by 6.17% to $197.2 million in 2023, then soared by 63.08% to $321.6 million in 2024, then slumped by 70.55% to $94.7 million in 2025, then grew by 19.69% to $113.4 million in 2026.
• Business Quant data shows NTLA's Change in Acquisitions & Divestments at $113.4 million in Q1 2026, $94.7 million in Q4 2025, and $115.9 million in Q3 2025.